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ABSTRACT 
 
 
Accumulating evidences indicate that dietary intake of long-chain 
polyunsaturated fatty acids (PUFAs) can affect various cellular processes and 
improve response of cancer cells to chemotherapy. The mechanisms by which 
PUFAs affect this response are not well understood. P-glycoprotein (P-gp), 
encoded by the multidrug resistance gene MDR1, is a drug efflux transporter that 
plays an important role in the bioavailability of anti-cancer drugs. Effects of long-
chain polyunsaturated fatty acids on MDR1 gene expression and functional 
activity in the human colon cancer cell line Caco-2 were studied in this research. 
Caco-2 cells were treated with different concentrations of three PUFAs: 
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid 
(AA). All three PUFAs down-regulated the expression of the MDR1 gene (EPA, 
34%, DHA, 32% and AA, 27%). The inhibition of gene expression by these 
PUFAs was accompanied by reduction in protein levels of P-gp. The calcein-AM 
efflux assay indicated that EPA, DHA, and AA can increase intracellular 
accumulation (hence decrease the efflux) of calcein-AM (a P-gp substrate) by 
25% to 31%. In addition, incubation of cells with PUFAs greatly enhanced the 
cytotoxicity of the anti-cancer drug paclitaxel. All three PUFAs also induced 
apoptosis and enhanced paclitaxel-induced apoptosis in Caco-2 cells. Together, 
these results suggest that inhibition of the multidrug resistance MDR1/P-gp is 
one mechanism through which dietary polyunsaturated fatty acids exert a positive 
effect on the response of tumor cells to anti-cancer drugs. In addition, 
 ii
transcriptional promotion of the nuclear receptors CAR and PXR by PUFAs was 
also observed in this study.  
Moreover, to determine whether the eicosapentaenoic acid affects BRCA1 
expression through promoter methylation, BRCA1 promoter methylation patterns 
and gene expression in U937 cells were examined. The methylation status of the 
BRCA1 promoter was evaluated by methylation-specific PCR (MSP) of bisulfite 
conversion products. The results indicate that methylation of BRCA1 promoter 
DNA is reduced in EPA-treated cells. The reduction of methylation in the BRCA1 
promoter was accompanied by an increase in mRNA levels obtained by real-time 
quantitative PCR (qPCR), suggesting that DNA methylation is a possible 
mechanism by which the dietary ω-3 polyunsaturated fatty acids mediate gene 
expression in human cells.  
Because of these characteristics, use of PUFAs as adjuvants presents a 
promising strategy in cancer prevention and therapeutics.  
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CHAPTER I 
INTRODUCTION 
 
Dietary polyunsaturated fatty acids (PUFAs) play important roles in cell 
physiology including control of cell division and cell growth, and they have been 
implicated in response to cancer therapeutics and in diseases of the 
cardiovascular system [1], obesity [2], diabetes [3], arthritis [4], bipolar disorder   
[5], as well as in cancer [6-8]. Studies demonstrate that ω-3 PUFAs can increase 
the sensitivity of tumor cells to anti-cancer drugs and suggest that there may be 
several means by which PUFAs are able to modulate this response [6, 9-12].  
The active efflux of a broad range of anticancer drugs through the cellular 
membrane is one mechanism by which a cell achieves multiple drug resistance 
(MDR) [13]. P-gp (phospho-glycoprotein), encoded by the MDR1 gene, is a 
membrane efflux transporter which facilitates the movement of cytotoxic drugs 
out of the cell and is overexpressed in MDR cells [14-16]. Variations in P-gp 
expression or activity may contribute to the therapeutic efficacy of chemotherapy 
[17-19]. The ability to inhibit the activity of MDR1 has been proposed as one 
mechanism by which ω-3 PUFAs affect cancer therapeutics [20], however, the 
mechanisms by which ω-3 fatty acids exhibit these effects are not fully 
established. 
Another mechanism by which components may affect response to anti-
cancer drugs is through transcriptional inactivation (by DNA hypermethylation) of 
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genes associated with cell cycle control [21, 22]. DNA methylation refers to 
covalent addition of a methyl group at the 5' carbon of the cytosine ring by DNA 
methyltransferases (DNMTs) to generate 5-methylcytosine [23]. DNA methylation 
inhibits binding of transcription factors to gene promoters leading to suppression 
of gene transcription [24]. BRCA1, a tumor suppressor gene, is repressed due to 
promoter hypermethylation in 11–31% of breast cancers, 5–15% of ovarian 
cancers, 60% of pancreatic ductal carcinomas, and 38% of acute myeloid 
leukemia [25-27].  
Although numerous studies link PUFAs to sensitizing cancer cells to anti-
cancer drugs, there is no research on whether PUFAs exert this ability by 
regulating the expression and function of MDR1/P-gp. Examinations of the effect 
of PUFAs on the expression/activity of MDR1 and on methylation/expression of a 
tumor suppressor gene are among the studies undertaken to clarify the effects of 
PUFAs in cancer chemotherapeutics. 
 
Objectives: The results of my studies related to the following specific objectives 
are presented in manuscript form in Chapters III and IV.  
1. Evaluate possible mechanisms involved in modulation of MDR1/P-gp 
expression by PUFAs in Caco-2 cells. 
a. Determine the effect of the ω-3 PUFAs, eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) and the ω-6 PUFA arachidonic acid 
(AA) on the expression of the MDR1 gene, levels of its encoded P-gp 
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protein and its efflux function in the human colon cancer cell line Caco-
2.  
b. Determine the effects of PUFAs on the sensitivity of Caco-2 cells to the 
anti-cancer drug paclitaxel and paclitaxel-induced apoptosis.  
c. Determine the effect of PUFAs on the expression of nuclear receptors 
CAR and PXR. 
2. Evaluate the effect of PUFAs on gene methylation 
Determine the effect of EPA on the methylation status and expression of 
the tumor suppressor gene BRCA1 in human leukemic U937 cells.  
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Polyunsaturated fatty acids (PUFAs) 
 
2.1.1. Structure and metabolic pathways 
Polyunsaturated fatty acids (PUFAs) are carboxylic acids containing 
double bonds. There are two categories of PUFAs, ω-6 (omega-6) and ω-3 
(omega-3), distinguished by the position of the first double bond from the methyl 
terminus of the hydrocarbon chain. Longer ω-6 and ω-3 PUFAs are metabolized 
from shorter chain precursors by a series of elongation and desaturation 
reactions (Figures 2.1 and 2.2) [6, 28, 29]. Linoleic acid (LA; 18:2ω-6) is 
converted to arachidonic acid (AA; 20:4ω-6), and α-linolenic acid (α-LNA; 18:3ω-
3) is converted to eicosapentaenoic acid (EPA; 20:5ω-3) and docosahexaenoic 
acid (DHA; 22:6ω-3).  
Twenty-carbon fatty acids of both families (e.g. dihomo-gamma-linolenic 
acid,  arachidonic  acid,  eicosapentaenoic  acid)  can  derive to different 
eicosanoids including leukotrienes (LT), prostaglandins (PG) and thromboxanes 
(TX) [28], metabolites known to be involved in  different and conflicting aspects of 
tumor cell metabolism (Figure 2.2).  
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 Figure 2.1. Synthesis pathways of long-chain polyunsaturated fatty acids [6]. The 
fatty acids linoleic acid (LA) and α-linolenic acid (α-LNA) compete for metabolism 
through a series of enzymes (desaturases and elongases). LA and α-LNA are 
converted to arachidonic acid (AA) and eicosapentaenoic acid (EPA), 
respectively, through a sequential action of delta 6 fatty acid desaturase (∆6), 
elongase (elo), and delta 5 fatty acid desaturase (∆5). EPA is further elongated to 
docosapentaenoic acid (DPA), desaturated by delta 4 fatty acid desaturase (∆4) 
to form docosahexaenoic acid (DHA). DPA can also be elongated to 
tetracosapentaenoic acid (TPA), desaturated to tetracosahexaenoic acid (THA) 
by ∆6 desaturase, translocated to peroxisomes, and β-oxidized (β-oxi) to 
docosahexaenoic acid (DHA) (Sprecher pathway).  
 
2.1.2. Sources  
LA and α-LNA cannot be synthesized by mammalian organisms due to the 
lack of required desaturase enzymes (∆12 and ∆15). Therefore, these two 
PUFAs are essential and must be obtained from diet to maintain physical 
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functions. Sources of LA are vegetable seeds and oils (soybean, coconut, corn 
and sunflower), while sources of α-LNA are dark green leafy plants and perilla, 
linseed, rapeseed, walnut, canola oil, flaxseed and blackcurrant seed oils [28]. 
The longer-chain EPA and DHA are found in cold-water fatty fish such as tuna, 
salmon, herring, sardines and mackerel [30, 31]. EPA and DHA can be produced 
from α-LNA by human beings; however, the extent of this conversion is inefficient 
(< 5–10% for EPA and 2-5% for DHA) [30, 31], such that EPA and DHA are 
acquired mainly through consumption of fish.  
 
Figure 2.2. Pathways of ω-6 and ω-3 PUFAs metabolism and effects on tumor 
biology [28]. ω-6 and ω-3 fatty acids are metabolized through a series of 
enzymes (desaturases and elongases). Twenty-carbon fatty acids of both 
families (dihomo-gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid) 
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derive to different series of eicosanoids which include leukotrienes (LT), 
prostaglandins (PG) and thromboxanes (TX). 
 
Intake of PUFAs leads to their incorporation into membrane phospholipids 
[32, 33], and diet significantly influences the lipid composition of cell membranes. 
The relative amounts and types of dietary PUFAs consumed are believed to be of 
critical importance in determining the effects of PUFAs on cell function. 
 
2.1.3. Effects of PUFAs on human health  
Over the past 40 years, increasing evidence indicates that ω-6 and ω-3 
PUFAs impact numerous processes in the body (Figure 2.3) [34, 35]. These 
dietary polyunsaturated fatty acids (PUFAs) have been implicated in diseases of 
the cardiovascular system [1], obesity [2], diabetes [3], arthritis [4], bipolar 
disorder [5], as well as in cancer [6-8].  
The mechanisms by which PUFAs are thought to affect cellular function 
are (1) modulation of eicosanoid production [36, 37]; (2) alteration of membrane 
fluidity or permeability [38, 39]; (3) changes in the production of lipid second 
messengers [40, 41]; (4) incorporation into lipid rafts, leading to changes in the 
distribution and/or activity of raft-related signaling proteins [35, 42]; (5) 
modulation of gene expression [43]; (6) modulation of gene expression via 
activation of peroxisome proliferator-activated receptors [44]; and (7) modulation 
of transcription factor activity [45, 46].  
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 Figure 2.3. Effects of PUFAs on cell functions [35]. Fatty acids regulate some 
transcription factors by direct binding or by controlling mechanisms that affect 
nuclear abundance or activity of the transcription factors. 
 
Of particular interest, studies have demonstrated that ω-3 PUFAs can 
increase the sensitivity of tumor cells to anti-cancer drugs in cell culture and in 
tumor-bearing animals. For example, DHA and/or EPA enhance the cytotoxic 
effect of several anti-cancer drugs including doxorubicin [47], epirubicin [48], 
taxane [49], 5-fluorouracil [50], mitomycin [51], arsenic trioxide [52], and 
tamoxifen [53] in cell lines derived from human neoplasms (e.g. breast, colon, 
bladder cancers). In animal studies, treatment with combinations of anti-cancer 
agents and ω-3 PUFA resulted in decrease of tumor size [48, 54, 55], reduction 
of side effects [56-59] and increased survival time [60]. In clinical studies, 
administration of the anti-cancer agents with PUFAs also resulted in the 
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improvement of nutritional status and quality of life assessments [61] and 
significant increase of body weight and energy level [62]. 
 
2.1.4. Mechanisms by which ω-3 PUFAs may enhance efficacy of chemo-
therapeutic drugs 
The mechanisms by which ω-3 PUFAs exert a beneficial role as 
supplements before or during chemotherapy are still not clearly established. 
Elucidation of these mechanisms is essential to ensure optimal efficacy of 
chemotherapy drugs and optimal influence of target levels within patients 
receiving supplements of ω-3 PUFA. Potential mechanisms examined include [10] 
(1) enhancement of drug uptake or intracellular accumulation [14, 63]; (2) 
alteration of membrane-associated signal transduction factors [53, 64]; (3) 
decreasing NF-κB activity [45, 64-66]; (4) lipid peroxidation [47]; (5) modulating 
expression or function of apoptotic proteins [48, 67, 68] and (6) enhancement of 
nucleoside analogue drug activity [69]. These potential pathways are discussed 
below. Of note, unlike many chemotherapy agents used, ω-3 PUFA 
administration does not appear to have toxic effects on normal cells [70]. 
 
2.1.4.1. Enhancement of drug uptake or intracellular accumulation  
Studies have demonstrated that incorporation of ω-3 PUFAs into cell 
membranes modifies membrane permeability and fluidity in vivo [71] and in vitro 
[38]. A consequence is modification of the influx and efflux of drugs (particularly 
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hydrophobic drugs that pass through the membrane by diffusion) into and/or out 
of tumor cells [72]. (See discussion in MDR section) Increased drug uptake is 
also related to an effect of ω-3 PUFAs on transport proteins within the membrane 
[10].  
 
2.1.4.2. Alteration of membrane-associated signal transduction factors  
Among the membrane associated signaling factors that may be affected 
by PUFAs are Ras proteins, Akt activity and Her-2/Leu protein levels. Ras 
proteins are guanine-nucleotide binding proteins that cycle between inactive 
GDP-bound and active GTP-bound forms. They promote tumor cell growth, 
differentiation, survival and resistance to apoptosis [73], and  association with 
lipid membranes is necessary for their function [74]. In colon tumor bearing rats 
fed a high fat fish oil diet, there are decreased levels of membrane bound Ras, 
increased levels of cytosolic Ras and decreased activity of farnesyl transferase 
compared to rats fed a high fat corn oil diet [75, 76]. Further, in vitro studies 
indicate that mouse colon cells treated with DHA have decreased Ras GTP 
binding/localization to the plasma membrane, compared to cells treated with 
linoleic acid [77]. These results suggest that ω-3 PUFAs may affect Ras 
activation by changing its membrane localization. 
The PI3K/Akt signaling pathway plays an important role in cell cycle 
progression, affecting cellular functions including proliferation, apoptosis, 
differentiation and chemotaxis. Cells are protected from apoptosis by Akt, which 
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inactivates components needed for cell apoptosis pathways (e.g., caspase-9 and 
BAD). In addition, Akt can indirectly promote cell survival by activating NF-κB, a 
pro-survival transcription factor [78]. EPA and/or DHA decrease both Akt 
phosphorylation [64] and activity [53] in vitro,  and EPA renders breast cancer 
cells with high Akt activity more responsive to the anti-cancer drug, tamoxifen 
[53].  
Overexpression of Her-2/Leu, a transmembrane tyrosine kinase receptor 
belonging to the epidermal growth factor family, leads to taxane-based resistance. 
Therefore, tumor cells are more sensitive to taxanes when Her-2/Leu is down-
regulated [79, 80]. For example, treating Her-2/Leu-overexpressing breast cancer 
cells with DHA reduced Her-2/Leu protein expression and enhanced the cytotoxic 
effects of paclitaxel and docetaxel [49].  
 
2.1.4.3. Activity/expression of NF-κB  
Nuclear factor-κB (NF-κB) is a transcription factor that plays an important 
role in cellular survival, growth, differentiation, adhesion and inflammation [81]. 
NF-κB acts as a promoter of tumorigenesis because it regulates genes (e.g., 
cyclin D1, bcl-2, bcl-x, matrix metalloproteinases) related to cell survival and 
inhibition of apoptosis. Patients with breast tumors that express activated NF-κB 
prior to chemotherapy treatment have a lower clinical response than patients with 
undetectable NF-κB staining [82]. Other studies have shown that inhibition of NF-
κB expression can enhance sensitivity of tumor cells to chemotherapeutic drugs 
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[81, 83-86]. Long-chain ω-3 PUFAs decrease NF-κB activity or expression in 
human breast cancer cells [64, 66], macrophages [45] and T cells [87]. These 
studies suggest that ω-3 PUFA may be able to sensitize tumor cells to 
chemotherapy by decreasing NF-κB activity or expression.  
 
2.1.4.4. Lipid peroxidation 
Long-chain ω-3 PUFAs are susceptible to free radical attack, leading to 
formation of lipid hydroperoxides. The major effects of lipid peroxidation are 
inhibition of DNA synthesis, cell division and tumor growth, and induction of 
tumor cell death [88-90].  
Drugs belonging to the anthracycline family of chemotherapeutic drugs 
(e.g., doxorubicin, epirubicin and daunorubicin) are thought to induce tumor cell 
death by stimulating formation of oxygen free radicals, which causes irreversible 
cell damage [91]. Addition of an oxidant such as DHA was reported to enhance 
cytotoxicity of doxorubicin in human breast cancer cells. This effect was 
decreased by addition of an antioxidant such as α-tocopherol [92]. Further, the 
efficacy of doxorubicin in treatment of mammary tumors is increased in mice fed 
fish oil (3%, w/w) 5 weeks prior to chemotherapy [55]. DHA is also reported to 
enhance the efficacy of arsenic trioxide, an antineoplastic agent used in 
treatment of acute promyelocytic leukemia, by inducing apoptosis through a 
reactive oxygen species-dependent pathway [52].  
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2.1.4.5. Modulation of expression or function of apoptotic proteins   
Most chemotherapeutic drugs are believed to kill tumor cells by inducing 
or increasing apoptosis [93, 94]. Resistance to apoptosis can result in a decrease 
in tumor cell sensitivity to many chemotherapeutic agents. Therefore, agents that 
can increase expression of pro-apoptotic proteins and down-regulate anti-
apoptotic proteins may be able to increase the efficacy of standard 
chemotherapies. Recent findings also demonstrate that most anti-cancer agents 
induce apoptosis through modification in tumor cell membrane fluidity (reviewed 
in [95]). 
There is extensive evidence that ω-3 PUFAs can regulate expression or 
activity of apoptotic proteins in tumor cells (reviewed in [96]). DHA or EPA 
decrease the expression of the anti-apoptosis proteins in many cancer cells [67, 
68, 97-99] and the combination of DHA and 5-fluorouracil decreases expression 
of bcl-2 and bcl-xL more than either agent alone [100]. 
 
2.1.5. The roles of ω-6 PUFAs in tumor biology 
Whereas long chain ω-3 PUFAs show inhibitory effects on cancer, ω-6 
PUFAs are widely considered as factors promoting the development of tumors 
[101, 102]. Linoleic acid (LA) has been identified as an agent in dietary fat 
responsible for an up-regulation of tumor growth in vivo [103]. However, the ω-6 
PUFA arachidonic acid (AA) has been shown to exert a pro-apoptotic effect in 
many cell lines including HCT116 and U937 [104, 105]. Among the mechanisms 
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suggested to account for this effect are the ability of AA to (1) activate caspase-3 
dependent and shingomielyn-ceramide apoptosis pathways [104, 106, 107]; (2) 
induce mitochondrial permeability transition and cytochrome c release [108]; (3) 
up-regulate transcription factors such as AP-1 involved in apoptosis [104, 109, 
110]; (4) induce cellular oxidative stress [111].   
 
2.2. Multidrug Resistance (MDR) 
 
A focus of this study was to determine the effect of PUFAs on tumor 
biology through modulation of multidrug resistance (MDR) (see Chapter III). A 
tumor is defined as anti-cancer drug resistant if the drug dosage in the tumor is 
not effective in achieving a clinically ascertained response [112]. Anti-cancer 
multidrug resistance is defined as the ability of cancer cells to survive in the 
presence of chemotherapeutic drugs of dissimilar structure and function [19, 113, 
114]. Despite remarkable progress in the last decades in understanding the 
molecular mechanisms leading to cellular resistance to anti-cancer drugs and the 
clinical introduction of new agents, MDR is still a major reason of therapy failure 
in the clinical treatment of cancer patients [112, 115-118].  
Various cellular pathways and molecular mechanisms may occur 
simultaneously and/or sequentially lead to the multi-drug resistance (Figure 2.4) 
[16]. Mechanisms implicated in MDR include (1) decreased drug uptake and 
increased drug efflux [119]; (2) induction of repair of drug-induced DNA damage, 
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e.g. induction of MGMT (O6-methylguanine-DNA methyltransferase) expression 
[120]; (3) activation of detoxifying systems, e.g. cytochrome P450 oxidases [121, 
122]; (4) blocked apoptosis, e.g. disruptions in p53 or ceramide apoptotic 
signaling pathways [123, 124]. Other factors that may contribute to MDR are the 
tumor microenvironment, e.g. vascularization, diffusion, hypoxia [125] and the 
architecture of barriers such as the blood brain barrier [126, 127]. 
 
Figure 2.4 Mechanisms of cellular multidrug resistance [16]. 
 
Drug influx/intracellular retention is important in achieving sufficient 
targeting of an anti-cancer drug to the tumor. Membrane transporters/carriers or 
hydrophilic channels are required for delivery of hydrophilic drugs such as 
cisplatin, nucleoside analogues and antifolates [128, 129]. Decreased 
intracellular accumulation for this kind of anti-cancer drug is due to defective 
transporter/carrier systems [130]. For hydrophobic drugs, such as the natural 
products vinblastine, vincristine, doxorubicin, daunorubicin, actinomycin D, 
etoposide, teniposide, and paclitaxel, drug entry occurs by diffusion across the 
plasma membrane, without any specific drug carriers. Activation of energy-
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dependent  transport  systems, such as ATP-binding cassette (ABC) transporters, 
is able to keep these drugs out of cells [131, 132].   
The ATP-binding cassette transporters share similar sequence and 
structure. So far, 48 human ABC genes have been identified. They can be 
divided into seven distinct subfamilies (ABC-A–>ABC-G) on the basis of their 
sequence homology and domain organization [133]. The first efflux transporter 
that was identified as mediating a multidrug-resistant phenotype in an in vitro 
model was the P-glycoprotein (P-gp) [134-136] (see below).  
 
2.3. P-glycoprotein (P-gp) 
 
P-gp, encoded by the MDR1 (ABC-B1) gene, is a broad-spectrum 
transporter expressed in the enterocytes at the villus tip of the small intestine, 
hepatocytes, renal proximal tubular cells and capillary endothelial cells 
comprising the blood-brain barrier [137]. P-gp acts as a barrier to uptake of 
xenobiotics by promoting expulsion of different classes of cytotoxic agents from 
cells (Table 2.1[16] and Table 2.2 [132]).   
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Table 2.1. Tissue localization and possible functions of P-gp (modified from [16]) 
Chemotherapy 
substrates  Common 
Name 
Systematic 
name 
Tissue 
Non-
Chemotherapy 
substrates 
(known and 
suspected) 
Intestine Doxorubicin MDR1/ 
P-gp ABCB1 Liver Daunorubicin 
Kidney Vincristine 
  Placenta 
Neutral and cationic 
organic compounds 
many commonly 
used drugs Vinblastine 
   Actinomycin-D 
   Paclitaxel 
Blood-
brain 
barrier Docetaxel 
 Etoposide 
    Teniposide 
    Bisantrene 
    Homoharringtonine
    (STI-571) 
 
P-gp has 12 transmembrane regions and two ATP binding domains 
(Figure 2.5). Substrates bind to the transmembrane domains and are exported to 
extracellular space by the energy of ATP hydrolysis [138]. Two ATP hydrolysis 
events, which do not occur simultaneously, are needed to transport one drug 
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molecule [139]. Binding of substrate to the transmembrane domains stimulates 
the ATPase activity of P-gp, causing a conformational change that releases 
substrate from membrane [140]. Hydrolysis triggered at the second ATP site 
seems to be able to reboot  the transporter so that it can bind substrate again, 
completing one catalytic cycle [141].  
membrane 
out 
 in 
 
Figure 2.5. Structure of P-gp (modified from [16]). P-gp has 12 transmembrane 
domains and two ATP binding sites. The line attached to ATPs is protein strand. 
N: amino-terminal; C: carboxy-terminal.  
  
Overexpression of P-gp results in lower levels of anti-cancer drugs in the 
blood and reduced diffusion of drugs from the blood into the tumor mass [142]. 
There is increased tissue concentrations of P-gp substrates in Mdr1a/Mdr1b-
knockout mice [16, 143], and when a P-gp inhibitor is administered with P-gp 
substrates, there is increased absorption of the substrates into tissue [144, 145].  
Ample evidences show that expression levels of MDRI impact cancer 
recurrence [15, 146]. MDR1 is expressed at high levels in many cancers, 
including kidney, liver, and colon cancer. For some cancers (leukemias 
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lymphomas, and multiple myeloma), P-gp levels are low at beginning, however, 
the levels elevate when recurrence occurs after chemotherapy. In other cancers, 
including chronic myelogenous leukemia in blast crisis and neuroblastoma, the 
development of the tumor appears to be associated with the turning on of P-gp 
expression [15].  
These observations support the use of inhibitors for P-gp as a strategy to 
increase the bioavailability of a chemotherapeutic drugs [142]. A number of 
inhibitors/mediators of ABC-transporters have been identified/developed over the 
past years (reviewed in [147]). The hope was that these “drug resistance factor-
targeting” compounds would reverse/inhibit the ability of drug resistance in 
cancer cells, thereby enhancing the efficacy of the anti-cancer drugs. Un-
fortunately, there have been unsatisfactory results in clinical trials, with unwanted 
side effects [112, 148]. For example, the necessary concentration of verapamil 
for blocking P-gp in tumors resulted in cardiac toxicity [149], and a Phase III  trial 
with tariquidar, a third-generation inhibitor, was abandoned due to problems with 
toxicity [150]. Other approaches to modify efflux pump function have included the 
development of monoclonal antibodies directed against an extracellular epitope 
of MDR1/P-gp [151] and RNA interference (RNAi) approaches [152]. However, 
co-administration of an anti-cancer drug with a chemosensitizer that impairs P-gp 
function is still the basic strategy to circumvent MDR. Selected substrates and 
modulators of P-gp are listed in Table 2.2 [132].  
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Table 2.2 Substrates and modulators of P-gp [132] 
Substrates Modulators 
Vinca alkaloids Calcium channel blockers 
     Vinblastine      Verapamil 
     Vincristine      Dihydropyridines 
Anthracyclines Antiarrhythmics 
     Daunorubicin      Quinine 
     Doxorubicin Antihypertensives 
Antibiotics      Reserpine 
     Dactinomycin Antibiotics 
     Actinomycin D      Cephalosporins 
Other cytotoxic agents Immunosuppressants 
     Mitomycin      Cyclosporin A 
     Taxol Steroid hormones 
     Colchicine      Progesterone 
     Puromycin HIV protease inhibitors 
     Digoxin      Sequinavir 
 Alcoholism treatment drug 
      Disulfiram 
 Phytochemical 
       Curcumin 
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2.3.1. Transcription of P-gp 
Expression of the ABC transporters is highly regulated, particularly at the 
level of transcription [153]. Some studies indicate that the expression of drug 
transporter genes can be enhanced in response to chemotherapeutics [154, 155].  
Although it was believed that only the MDR-drugs can induce the genes, recent 
studies indicate that non-MDR drugs , antifolates and hydoxyurea , may also 
induce MDR1 transcription [156]. 
We have observed that exposure to PUFAs reduces the expression of 
MDR1 in Caco-2 cells (see Chapter III). Caco-2 cells, derived from a human 
colonic adenocarcinoma, express P-gp and other multiple drug resistance 
proteins at levels similar to those in normal small intestinal epithelial cells and are 
an appropriate model for studying the effect of PUFAs on P-gp [157, 158]. Our 
results also indicate that in cells where MDR1 expression was reduced, the efflux 
function of MDR1/P-gp was decreased and paclitaxel toxicity increased. These 
observations are consistent with the thesis that inhibition of MDR1 gene 
expression accounts, at least in part, for the ability of PUFAs to increase the 
bioavailability of anti-cancer drugs, i.e. counteracts MDR1-mediated drug 
resistance, in cancer cells.  
      
2.3.2. Other factors affecting P-gp expression and activity 
2.3.2.1. Nuclear receptors  
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Binding of agonist ligands to a heterodimers of nuclear proteins such as 
the retinoid X receptor (RXR) results in dissociation of a repressor protein from 
the complex and recruitment of a co-activator protein that in turn promotes 
transcription of the downstream target gene into mRNA. Nuclear receptor 
proteins that have been shown to be involved in transcription of drug transporters 
include the retinoic acid receptor (RAR), farnesoid receptor (FXR), the steroid-
activated receptor (SXR), the pregnane X receptor (PXR) and the constitutive 
androstane receptor (CAR) [159-161].  
 
2.3.2.2. Methylation status of local chromatin 
Chromatin is transcriptionally inactive in its basal state because DNA in a 
nucleosomal complex is generally inaccessible to transcription factors. However, 
signals from the environment can trigger conformation changes in chromatin that 
alter transcription potential. Promoter-hypomethylated DNA is transcriptionally 
active, whereas promoter- hypermethylated DNA is transcriptionally inactive (see 
below). Chromatin-modifying enzymes, i.e. histone acetylases, histone 
deacetylases and DNA methylases are involved in the regulation of the MDR1 
gene [162, 163].  
 
 2.3.2.3. The Ras signaling pathway 
The MDR1 gene is also a target of the ras/raf signaling pathway [164, 165]. 
The activation of the MDR1 promoter occurs in the presence of an activated H-
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Ras oncogene [166]. Of note, mutations of Ras oncogenes result in down-
regulation of MDR1 expression in acute myeloid leukemia [164].   
 
2.3.2.4. Inflammation  
The MDR1 gene responds to stress signals such as inflammation [167]. 
Under inflammatory conditions, the MDR1 gene is induced in the liver [168]. 
Cyclooxygenase-2 (COX-2) and its product, prostaglandin E2 (PGE2), are 
involved in inflammatory responses [169] and  overexpression of COX-2 results 
in upregulation of MDR1 expression [170, 171] .  
 
2.3.2.5. P-gp and apoptosis 
Apoptosis is one of the main types of programmed cell death, and is 
commonly associated with activation of caspases. Apoptosis may also be 
caspase-independent [172]. A link between expression of MDR1/P-gp and 
cellular apoptotic pathways has been shown [173, 174]. For example, cancer 
cells expressing MDR1/P-gp exhibit resistance to anti-cancer drugs that trigger 
apoptosis. This response is associated with the blocking of mitochondrial 
cytochrome c release into the cytosol [175, 176]. This anti-apoptotic feature of  
MDR1/P-gp-expressing cancer cells appears to be dependent on the over-
expression of  Bcl-XL [112]. 
 
2.3.2.6. Effect of membrane composition on P-gp activity 
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Membrane composition and fluidity plays an important role in modulating 
activity of P-gp [177].  P-gp is located in cholesterol and sphingolipid-enriched 
domains of the plasma membrane called lipid rafts [178]. Removal of cholesterol 
from membranes changes P-gp localization and results in loss of P-gp function 
[179], and the inhibition of P-gp activity by excipients such as PEG are reported 
to be related to changes in membrane fluidity [180].  
 
2.4. DNA methylation in mammalian cells 
 
2.4.1. Epigenetic modifications 
Epigenetic change is defined as a change in gene expression maintained 
through cell divisions, which is not due to a change in DNA sequence [21, 181]. 
Within cells, histone proteins bind to DNA and organize chromatin into a compact 
form to fit into nucleosomes [182]. Epigenetic modifications, including DNA 
methylation and histone post-translational modifications, affect chromatin 
structure and gene transcription (Figure 2.6) [183].  
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 Figure 2.6. Epigenetic modification: DNA methylation and histone modification 
[184]. 
 
In DNA methylation there is covalent addition of a methyl group at the 5' 
carbon of the cytosine ring to produce 5-methylcytosine (Figure 2.7) [23]. There 
are two components involved in mammalian DNA methylation: the DNA methyl-
transferases (DNMTs) that establish and maintain DNA methylation patterns, and 
the methyl-CpG binding proteins (MBDs) that recognize methylation sites (Figure 
2.8) [185]. In mammalian DNA, cytosines in cytosine-phosphate-guanine 
dinucleotides (CpGs) are highly (70-80%) methylated [186]. These methyl groups 
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protrude into the major groove of DNA and can effectively inhibit transcription 
[187]. 
 
Figure 2.7. Structures of cytosine and 5-methylcytosine [183]. The DNMT 
enzymes use S-adenylmethionine (SAM) as the methyl donor to add a methyl 
group to the 5’ carbon of the cytosine ring. 
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Figure 2.8. DNA methylation and histone deacetylation cooperate to repress 
transcription [185]. Hyperacetylated and hypomethylated chromatin regions result 
in a transcriptionally active state. A DNA or a gene destined for silencing recruits 
DNA methyltransferases. The resulting methylated DNA recruits methyl-CpG 
binding proteins and histone deacetylases. The DNA will then be heritably 
maintained in an inactive state. 
 
2.4.2. DNA methylation and cancer 
DNA methylation plays an important role affecting cellular function, and 
alternation in methylation patterns may lead to tumorigenesis [188-191]. The 
changes in DNA methylation patterns that are commonly observed in cancer cells 
are outlined in Figure 2.9 [189]. In cancer cells there is often hypo-methylation in 
repetitive regions, which leads to genomic instability [192-194], as well as 
activation of normally silenced repetitive DNA elements [195].  
De novo methylation of CpG rich regions of DNA (CpG islands), often 
associated with the promoters of genes, can also occur during tumor 
development. An average of 600 CpG islands aberrantly methylated in tumors 
[196]. This number can vary widely between tumor types [196]. Studies indicate 
that DNA methylation inhibits binding of transcription factors to gene promoters 
leading to suppression of gene transcription [24]. Transcriptional inactivation of 
genes associated with cell cycle control, apoptotic signaling and DNA repair by 
DNA hypermethylation contributes directly to carcinogenesis and tumor 
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development [21, 22]. Of note, silencing of a specific tumor suppressor gene 
through DNA methylation affects the growth rate of cancer cells [197].  
 
Figure 2.9. Altered DNA-methylation patterns in tumorigenesis [189]. 
 
2.4.2.1. DNA methylation as a biomarker for cancer 
Improved clinical outcome of most cancers can be achieved by early 
detection. Therefore, development of early detection is important [198]. Because 
of their frequency and early occurrence in carcinogenesis, changes in DNA 
methylation, particularly CpG island hypermethylation, have been extensively 
examined as a method for early detection of cancers [199]. Methylation specific 
PCR (MSP) are sufficient and sensitive to detect promoter hypermethylation in 
serum, plasma, urine and fecal material [200]. Studying epigenetic profiles, DNA 
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methylation patterns and histone analysis, is expected to provide guidance for 
optimization of the epigenetic therapies with conventional chemotherapy and 
tools of diagnosis and prognosis [21, 184]. Several cellular pathways [201] 
targeted for aberrant DNA methylation-mediated gene silencing are listed in 
Table 2.3. 
 
Table 2.3. Cellular pathways affected by DNA promoter CpG island hyper-
methylation of tumor genes (modified from [201]) 
Pathways Representative hypermethylated genes  
DNA repair 
Vitamin response 
Ras signaling 
Cell cycle 
P53 network 
Cell adherence and invasion 
Apoptosis 
Wnt signaling 
Transcription factors 
Other pathways 
hMLH1, MGMT, BRCA1 
RARB2, CRBP1 
RASSF1A, NORE1A 
p16INK4a, p15INK4b, Rb 
p14ARF, p73, HIC-1 
E-cadherin, H-cadherin, EXT-1 
TMS1, DAPK1, WIF-1, SFRP1 
APC, DKK-1, IGFBP-3 
GATA-4, GATA-5, ID4 
GSTP-1, COX-2, TPEF/HPP1 
 
2.4.2.2. DNA methylation as a target for chemoprevention  
Genes silenced by DNA methylation are intact and can be reactivated by 
inhibitors of the DNMTs [199]. Targeting DNA methylation and DNA methyl-
transferases thus provides a promising strategy for cancer treatment [22]. DNMT 
inhibitors dramatically reduce the incidence of colon cancer [202]. Further, 
changes in DNA methylation can be readily detected with non-invasive assays. 
Thus drugs that target DNA methylation or DNMTs are now at the forefront of 
cancer treatments [184].  
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Methylation inhibitors (or hypomethylating agents) belong to three classes: 
(a) nucleoside inhibitors; (b) non-nucleoside inhibitors; and (c) rationally-designed 
inhibitors [203]. These inhibitors operate by reversing aberrant promoter 
hypermethylation, resulting in gene reactivation and restoration of cell growth 
control, apoptosis and DNA repair capacity [204-206]. Two nucleoside inhibitors, 
5-azacitidine and Decitabine (Figure 2.10), have been approved by the FDA and 
are now in clinical use for myelodysplastic syndrome (MDS) and acute myeloid 
leukemia (AML) [183, 207].  
The cytosine analogues are incorporated into newly synthesized DNA 
during replication. When DNMTs catalyst the analogues, a covalent complex is 
formed [208]. This results in trapped DNMT at these sites. Trapped DNMT 
enzymes cause enzyme degradation, lower DNMT levels, and ultimately, 
hypomethylation [183].  
Unfortunately, when used in high doses, these azanucleosides can 
produce serious toxicities in patients [203, 209]. As a single agent therapy for 
MDS, the most success for these drugs has been obtained using low doses and 
more cycles of therapy [210]. However, the effect of nucleoside inhibitors on 
gene activation is non-specific and usually involved in multiple cellular pathways 
[187, 203, 211, 212]. Thus, these demethylating agents may not suitable for 
application in cancer prevention (requiring long-term administration) due to safety 
concerns. Other agents such as procainamide [213], zebularine [214] and 
valproic acid [215] have shown the capacity to reverse DNA methylation and may 
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be safer for long-term use.   
 
Figure 2.10. Structures of the two FDA-approved hypomethylating agents, 5-
azacitidine and Decitabine [183].   
 
2.4.3. BRCA1/Cancer/DNA methylation 
BRCA1 is known to be involved in repair of DNA oxidative lesions [216, 
217] and in induction of cell cycle arrest and apoptosis [218]. The BRCA1 gene 
plays a major role in the genesis of breast and ovarian tumors [219-221]. 
Germline mutations of BRCA1 appear in about 50% of patients with inherited 
breast cancer [222, 223]. Frequent loss of the wild-type allele in tumors of 
BRCA1 mutation carriers suggests that BRCA1 acts as a tumor suppressor gene 
[224].  
A decrease in BRCA1 expression [225], associated with inactivation of the 
promoter by methylation, has been found in some cases of sporadic breast 
cancer [226-228]. In addition, reduced BRCA1 expression is frequently observed 
in therapy-related AML (t-AML) and contributes to secondary leukaemogenesis 
[27].  
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Of especial interest, DNA methylation patterns are highly sensitive to the 
chemical environment [191, 229] and studies have suggested that bioactive 
components of food can modify DNA methylation patterns [230]. For example, 
tea catechins are effective inhibitors of human DNA methyltransferase-mediated 
DNA methylation in vitro [202, 231]. A number of dietary compounds have also 
been shown to impact methylation, raising the possibility that an individual’s diet 
may also influence DNA methylation [232]. A better understanding of the 
relationship between dietary components and cellular epigenetics could suggest 
ways of suppressing DNA methylation changes associated with aging and cancer 
[233]. 
Dietary ω-3 polyunsaturated fatty acids have already been reported to 
impact to prevent cancer (reviewed in [28, 234, 235]) and to increase the 
sensitivity to anti-cancer drugs [48, 52, 100]. Moreover, research shows that ω-3 
polyunsaturated fatty acids can increase BRCA1 transcription and protein levels 
in human breast cancer cell lines [236] and in vivo [237]. In our study, we 
examined whether ω-3 polyunsaturated fatty acids can increase BRCA1 gene 
expression through decreasing promoter DNA methylation. 
2.4.4. Analysis of gene methylation by bisulfite conversion and methylation-
specific PCR (MSP) 
The methylation status of DNA can be assessed using bisulfite conversion 
and methylation specific PCR (MSP), first described by Australian researchers in 
1992 [238]. In this protocol, sodium bisulfite converts unmethylated cytosines (C) 
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to uracil (U) while methylated cytosines remain unchanged (Figure 2.11). After 
conversion, PCR is performed using specific primer sets for unmethylated and 
methylated DNA [239, 240]. The MSP products can be sequenced, visualized by 
agarose gel electrophoresis or analyzed by qPCR.  
 
Figure 2.11   Bisulfite conversion (modified from [240]). DNA is denatured and 
treated with sodium bisulfite. PCR is performed with primers specific to one of 
two modified chains.  
 
Of note, bisulfite treatment of DNA has some limitations and shortcomings, 
e.g., a decrease in the sensitivity may occur because of incomplete conversion 
from cytosine to uracil or partial degradation of DNA caused during bisulfite 
treatment [241, 242]. A number of approaches have been developed to improve 
these drawbacks [243]. 
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CHAPTER III 
LONG-CHAIN POLYUNSATURATED FATTY ACIDS INHIBIT THE 
TRANSCRIPTION AND ACTIVITY OF MDR1/P-GP IN THE HUMAN COLON 
CANCER CELL LINE CACO-2 
 
ABSTRACT 
 
Accumulating evidence in both humans and animal models indicate that 
dietary intake of long-chain polyunsaturated fatty acids (PUFAs) can improve 
response to chemotherapy. The mechanisms by which PUFAs affect this 
response are not well understood. P-glycoprotein (P-gp), encoded by the 
multidrug resistance gene MDR1, is a drug efflux transporter that plays an 
important role in the bioavailability of anti-cancer drugs. Effects of long-chain 
polyunsaturated fatty acids on MDR1 gene expression and functional activity in 
the human colon cancer cell line Caco-2 were studied in this research. Caco-2 
cells were treated with different concentrations of three PUFAs; eicosapentaenoic 
acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (AA). All three 
PUFAs down-regulated the expression of the MDR1 gene (EPA, 34%, DHA, 32% 
and AA, 27%). The inhibition of gene expression by these PUFAs was 
accompanied by reduction in protein levels of P-gp. The calcein-AM efflux assay 
indicated that EPA, DHA, and AA can increase intracellular accumulation (hence 
decrease the efflux) of calcein-AM (a P-gp substrate) by 25% to 31%. In addition, 
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incubation of cells with PUFAs greatly enhanced the cytotoxicity of the anti-
cancer drug paclitaxel. All three PUFAs also induced apoptosis and enhanced 
paclitaxel-induced apoptosis in Caco-2 cells. Together, these results suggest that 
inhibition of the multidrug resistance MDR1/P-glycoprotein is one mechanism 
through which dietary polyunsaturated fatty acids exert a positive effect on the 
response of tumor cells to anti-cancer drugs. In addition, we have shown that 
PUFAs promote transcription of the nuclear receptors CAR and PXR. Our results 
support the notion for using PUFAs as promising adjuvants in cancer 
therapeutics.  
  
3.1. Introduction 
 
Dietary long-chain polyunsaturated fatty acids (PUFAs) are known to 
mediate numerous cellular processes [1, 2]. There are two main classes of 
PUFAs, omega-3 (ω-3) and omega-6 (ω-6), distinguished by the position of the 
first double bond at the methyl terminus of the hydrocarbon chain. Of particular 
interest, several studies have demonstrated that ω-3 PUFAs such as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) sensitize tumor-
bearing animals and tumor cells in culture to cytotoxicity of anti-cancer drugs [3-
6]. The mechanisms by which ω-3 fatty acids induce these effects are not fully 
established. 
There are conflicting reports concerning the effect of ω-6 PUFAs on tumor 
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cells. For example, over-expression of the ω-6 PUFA, arachidonic acid (AA), has 
been linked to induction of apoptosis in the human colon cancer cell line HCT116 
[7] and the human leukemic cell line U937 [8], but others have demonstrated that, 
unlike the ω-3 PUFAs, AA stimulates the growth of pancreatic and prostate 
cancer cells in vitro [9, 10].  
Treatment of cancer is complicated by the fact that cancer cells have the 
ability to become resistant to different anticancer drugs. The active efflux of a 
broad range of anticancer drugs through the cellular membrane is one 
mechanism by which a cell achieves multiple drug resistance [11]. The human 
multidrug-resistance MDR1 gene encodes the P-glycoprotein (P-gp), which 
functions as an energy-dependent membrane efflux pump for a wide variety of 
lipophilic compounds [12]. The P-gp protein plays an important role in multidrug 
resistance by decreasing the intracellular retention of many anticancer drugs [13-
15], thus preventing the interaction of these agents with their target molecules. 
Studies indicate that the MDR response is inversely related to the level of P-gp 
expression in various human cancers [16-18], suggesting that the ability to inhibit 
the activity of MDR1 has been proposed as one mechanism by which ω-3 PUFAs 
affect cancer therapeutics [19].  
The ability of PUFAs to modulate expression of nuclear receptor genes 
involved in drug metabolism [20] is another mechanism by which PUFAs may 
impact MDR1. The constitutive androstane receptor (CAR) [21] and the pregnane 
X receptor (PXR) [22] function by heterodimerizing with the retinoic acid x 
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receptor (RXR) and binding to response elements in the promoter regions of 
target genes [23]. They are reported to be involved in transcription of multiple 
drug transporters [21, 22, 24, 25], in particular to mediate MDR1 gene expression 
[25], and have been identified as candidates for mediating gene regulation by 
fatty acids [26, 27].  
Several pathways by which PUFAs may impact MDR were examined in 
this research.  Effects of the ω-3 PUFAs, EPA and DHA, and the ω-6 PUFA AA 
on the expression of the MDR1/P-gp gene and on the levels and function of its 
protein product in cells of the human colon cancer cell line Caco-2 were also 
investigated. To determine whether PUFAs can increase the efficacy of the anti-
cancer drug, paclitaxel, effects of PUFAs on paclitaxel-induced cytotoxicity were 
studied. Since cancer cells expressing MDR1/P-gp are more resistant to 
caspase-dependent apoptosis-triggering agents than normal cells [28, 29], 
whether PUFAs can enhance apoptosis in paclitaxel-treated Caco-2 cells was 
investigated. In addition, we evaluated whether PUFAs modulate MDR1/P-gp via 
regulation of two nuclear receptors, CAR and PXR, which are reported to be 
involved in modulation of the expression of MDR1.  
 
3.2. Materials and Methods 
 
3.2.1. Materials and reagents 
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The sodium salts of arachidonic and eicosapentaenoic acids were 
purchased from Nu-Chek Prep, Inc. (Elysian, MN). Paclitaxel and the sodium salt 
of docosahexaenoic acid were purchased from Sigma-Aldrich (St. Louis, MO).  
 
3.2.2. Cell culture 
Cultures of Caco-2 cells (human colorectal adenocarcinoma) at passage 
12 were obtained from the American Type Culture Collection (Manassas, VA, 
USA). For sub-culture, phosphate buffered saline (PBS) washed cells at 60-70% 
confluence were detached from the flask surface with 0.25% (w/v) trypsin-EDTA 
(0.022%, w/v) and centrifuged at 1,600 rpm for 5 min. Cell pellets were re-
suspended in complete medium at a ratio of 1:3 in T75 flasks and maintained at 
37°C in 5% CO2 and 95% humidity. Complete medium contains 10% bovine 
growth serum (BGS) in minimum essential medium (MEM) with the following 
supplements: 1% MEM nonessential amino acids, 1% sodium pyruvate, 100 U/ml 
penicillin and 100 μg/ml streptomycin. All reagents were purchased from Hyclone, 
Inc. (Logan, UT). Plastic ware for cell culture was obtained from Fisher Scientific 
(Pittsburgh, PA) and VWR (West Chester, PA). Caco-2 cells at passage 30 to 40 
were used for the experiments in this study.  
 
3.2.3. Preparation of the BSA/fatty acid complex  
Serum albumin serves as carrier for free fatty acids in blood [30]. Bovine 
serum albumin, a well-studied fatty acid carrier protein in vitro [30, 31], was used 
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as the PUFA carrier for these studies. To prepare BSA/PUFA complexes for 
application to cells, a modification of the method of Ho and Storch [32] was used.  
Briefly, BSA was coupled to PUFAs by adding the sodium salt of the fatty acid 
(0.01 g) to MEM medium (9mL) containing 825μM fatty acid-free BSA. The 
mixture was incubated at 37°C for 12 hr to obtain an optically clear solution, and 
aliquots of the BSA/fatty acid complex solution were stored under N2 gas at  
-20°C. The aliquots were filter-sterilized before addition to the experimental 
medium. The molar ratio of fatty acid to BSA was 4:1 [33].  
 
3.2.4. Cell viability  
Cell viability was measured every 24h for a 72h time period, using the 
CellTiter-Blue® reagent (CTB, Promega, Madison, WI). The viability assay is 
based on the ability of living cells to convert a redox dye (resazurin) into a 
fluorescent end product (resorufin). Nonviable cells rapidly lose metabolic 
capacity and thus do not generate a fluorescent signal.  
Caco-2 cells were seeded into flat-bottomed 96-well plates at a density of 
103 cells/well in a volume of 200 μl of complete medium. After a 24 hr incubation 
period to complete attachment, cells were exposed to 0–100 μM PUFA. As 
controls, cells were exposed to complete medium alone. After removal of 100 μl 
of the cell medium, 20 μl CTB reagent was added to the remaining 100 μl of well 
medium and cells were incubated at 37°C for 4 hr before quantization of 
fluorescence on a Synergy HT multi-mode plate reader (Bio-tek Instruments, 
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Winooski, VT) using an excitation wavelength of 560 nm and an emission 
wavelength of 590 nm. The fluorescence values were normalized to the controls 
and expressed as percent viability.  
 
3.2.5. RNA extraction and reverse transcription (RT) 
Caco-2 cells were seeded into T25 flasks at a density of 1.5 x 106 
cells/flask. After 24h to assure attachment, cells were exposed to 0–100 μM 
PUFAs. As controls, cells were exposed to complete medium alone. After 
incubation, cells were washed with PBS and trypsinized with 0.25% (w/v) trypsin-
EDTA (0.022%, w/v). Cells pelleted at 1,600 rpm for 5 min were resuspended in 
PBS. After DNAse I treatment to remove genomic DNA, total RNA was isolated 
using the SV Total RNA isolation kit (Promega, Madison, WI) according to the 
manufacturer’s instructions. The concentrations and purity of the RNA samples 
were assessed spectrophotometrically using the DU 640 spectrophotometer 
(Beckman Coulter, Fullerton, CA). RT was performed using the reagents 
provided in the Verso cDNA kit (Abgene, Rochester, New York). The RT reaction 
mixture (20 µl) contained 1 μg total RNA, 1 µl anchored oligo-dT primer, 500 µM 
dNTP mix, 4 ml 5× cDNA synthesis buffer, 1 µl RT enhancer and 1 µl Verso 
enzyme mix. RT was performed at 42°C for 30 min and terminated by heating at 
95°C for 2 min. cDNAs were stored at -20°C.  
 
3.2.6. Real-time quantitative PCR (qPCR )  
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Real-time quantitative PCR for MDR1, CAR, and PXR was conducted 
using an Mx3000P real-time PCR system (Stratagene, La Jolla, CA). The gene-
specific primers (Fisher-Operon, Huntsville, AL) used for qPCR are shown in 
Table 3.1 and after initial heating at 95°C for 2 min, amplification proceeded 
according to the PCR cycling information provided in Table  3.1.  
 
Table 3.1. Primers and cycling information 
 Annealing   Annealing  Amplicon  
Gene Forward sequence Reverse sequence 
  temp (°C) time (s) 
Cycle 
(bp) 
MDR1 GCTCCTGACTATGCCAAAGC TCTTCACCTCCAGGCTCAGT 60 40 40 202 
CAR GGGGTTCCAGGTAGAGTTT GTCGGTCAGGAGAGAAGAG 58 40 40 122 
PXR CGCTTCCTGAGTCTTTTCA CGCCTGCCGATGAGTACA 58 60 40 115 
β-Actin  CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 60 40 40 250 
 
All reactions were performed in a singleplex mode. The total reaction mix 
(20 μl) contained 10 μl 2x SYBR Green PCR master mix (Bio-Rad Laboratories, 
Hercules, CA), 200 nmol/L of each primer, and 0.8-1 μl cDNA as template. 
Dissociation curve analyses were done for all samples and only sharp melting 
points were observed, indicating a specific signal and no primer dimers or 
mispriming. A negative template control (H2O) was always included in each run 
to check for the presence of exogenous contaminant DNA. After the threshold 
cycle values in real-time PCR were obtained, the amounts of MDR1 were 
determined from a standard curve generated by serial dilutions of cDNA. After 
normalization to β-actin values, the expression levels of MDR1 for each condition 
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were expressed as % of control cells. Each sample was analyzed in triplicate, 
and data were analyzed using Mx3000P software (Stratagene, La Jolla, CA).  
 
3.2.7. Western blotting 
To prepare whole cell lysates, the cells were collected in lysis buffer (50 
mM Tris–HCl, pH 7.4, 1% Triton X-100, 0.25% sodium deoxycholate, 150 mM 
NaCl, 1 mM EDTA, 1 mM PMSF, 1 μg/ml of pepstatin A, 1 μg/ml of leupeptin, 1 
mM NaF, 1 mM Na3VO4), and  centrifuged at 13000xg for 30 min at 4 °C. Total 
protein was determined by the BCA (bicinchoninic acid) assay (Pierce, Rockford, 
IL) and samples were prepared for electrophoresis by boiling for 5 min in 30 μl 
SDS-sample buffer (Boston Bioproducducts, Worcester, MA). For each condition, 
30 μg of total protein was separated on 10% SDS-polyacrylamide gels and 
electro-transferred to PVDF membranes (Bio-Rad Laboratories, Hercules, CA). 
The membranes were blocked with blocking reagents of WesternBreeze® 
chromogenic kit (Invitrogen, Carlsbad, CA) and then incubated with anti-P-gp 
mAb (Abcam Cambridge, MA) or anti-β-actin mAb (Santa Cruz Biotechnology Inc. 
Santa Cruz, CA). The bands were detected using reagents provided in the 
WesternBreeze® chromogenic kit (Invitrogen, Carlsbad, CA). The relative 
intensity of each protein band was measured using the Quantity One software 
(Bio-Rad Laboratories, Hercules, CA). 
 
3.2.8. Measurement of drug efflux  
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The efflux function of P-gp was measured using reagents supplied in the 
VybrantTM Multidrug Resistance (MDR) Assay kit (Molecular Probes, Eugene, OR) 
[34]. This assay uses calcein acetoxymethyl ester (calcein-AM), a highly lipid 
soluble, non-fluorescent dye that penetrates the plasma membrane of cells, to 
measure the efflux function of P-gp. Once calcein-AM is inside the cell, the ester 
bond is cleaved, resulting in formation of the hydrophilic and fluorescent calcein, 
which is bound and pumped out of the cells by P-gp.  
For the assay, cells were seeded at 1.2 x 105 cells/well in 12-well plates. 
After 24 hr, the cells were treated with 100 μM PUFA for 24 hr and then 
harvested by trypsinization. Cell pellets were washed with PBS and resuspended 
in PBS containing calcein-AM (final concentration 0.25 μM). Cells treated with 
DMSO or 20 μM verapamil served as negative and positive controls, respectively. 
Cells were incubated at 37°C for 20 min, centrifuged at 1,600 rpm for 5 min, 
washed (3 times) and resuspended in cold PBS.  Calcein retention was 
measured by florescence at 494 nm for excitation and 517 nm for emission using 
a flow cytometer equipped with the CellQuest software (BD Biosciences, San 
Jose, CA).  
 
3.2.9. Effect of PUFAs on cell toxicity of paclitaxel  
Caco-2 cells were seeded into flat-bottomed 96-well plates at a density of 
103 cells/well in a volume of 200 μl of complete medium. After a 24 hr incubation 
period to complete attachment, cells were treated with 0-100 nM of the 
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anticancer drug paclitaxel (Sigma-Aldrich, St. Louis, MO), with or without addition 
of 100 μM PUFAs, for 72 hr. The medium and drugs were replenished at 24 hr to 
avoid inactivation. The results are presented as percent of the solvent control.  
 
3.2.10. Apoptosis 
A characteristic of apoptosis is the translocation of phosphatidylserine (PS) 
to the outer surface of the plasma membrane. Apoptosis of Caco-2 cells was 
assayed using The Vybrant® apoptosis assay kit #2 (Molecular Probes, Eugene, 
OR). The kit supplies green-fluorescent Alexa Fluor 488 annexin V and red-
fluorescent propidium iodide nucleic acid stain. The externalization of 
phosphatidylserine in apoptotic cells is detected via annexin V, a phospholipid-
binding protein that has a high affinity for PS. Propidium iodide stains necrotic 
cells with red fluorescence. After treatment with both probes, apoptotic cells show 
green fluorescence, dead cells show red and green fluorescence, and live cells 
show little or no fluorescence. 
For the assay, cells seeded in 12-well plates at a cell density of 5x105 
cells/well for 24 hr were treated with 2.5 nM paclitaxel with or without 100 μM 
PUFA for 72 hr. Paclitaxel and PUFAs were replenished at 24 hr to avoid 
inactivation of reagents. Cells washed with cold PBS were resuspended in 
annexin-binding buffer and incubated with annexinV-AlexaFluor 488 conjugate/ 
propidium iodide according to the supplier’s directions for 20 min at room 
temperature. Cells were then washed with PBS and the fluorescent images were 
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captured using an Axiovert 135 inverted microscope (Carl Zeiss, Thornwood, NY) 
with 485nm filter, Image-Pro 5.1 software (Media Cybernetics, Silver Spring, MD), 
and a ProResTM C10Plus digital camera (Chori Imaging Corporation, Yokohama, 
Japan).  
 
3.2.11. Evaluation of mRNA expression of nuclear receptors, CAR and PXR  
The effects of PUFAs (24h treatment) on the mRNA levels of the nuclear 
receptors, CAR and PXR, were evaluated using qPCR (Section 3.2.6). The 
primer sequences and PCR conditions are listed in Table 3.1.  
 
3.2.12. Statistical Analysis 
Experimental results were analyzed by a pairwise t-test using EXCEL 
package (Microsoft, Redmount, WA). 
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3.3. Results 
  
3.3.1. Effect of Polyunsaturated Fatty Acids (PUFAs) on the Viability of Caco-2 
Cells.  
Three polyunsaturated fatty acids, AA, EPA and DHA were selected for 
our studies of the mechanisms by which PUFAs contribute to the therapeutic 
efficacy of chemotherapy. Because polyunsaturated fatty acids can be toxic to 
human cell growth [35-37], cell viability studies were conducted to determine 
concentrations of PUFAs appropriate for subsequent experiments. Human colon 
cancer cell line Caco-2 was incubated with different concentrations of the three 
PUFAs for 24, 48, and 72 hr. Although inhibition generally increased somewhat 
when cells were treated with higher concentrations of PUFAs, all three PUFAs, 
even at the highest concentration of 100 μM, had a modest inhibitory effect (~ 
20% of solvent controls) on the growth of Caco-2 cells (Figure 3.1). After 24 hr 
incubation at concentrations of 50 and 100 μM, EPA appeared to have the most 
potential for inhibition of cell growth.       
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Figure 3.1. The effect of PUFAs on viability of Caco-2 cells. Cells were incubated 
for 24, 48, and 72 hours with 25, 50 and 100 μM of the following PUFAs: AA, 
EPA, and DHA. The viability of treated cells is presented as the means of cell 
number (± SD) compared to control (untreated) cells. For each experiment, n=3.  
* (P < 0.05); ** (P < 0.01); *** (P < 0.001) indicate significant differences from 
control values. 
 
3.3.2. Effect of PUFAs on MDR1 gene expression in the Caco-2 cells 
Whether PUFAs modulate the expression of the MDR1 gene in Caco-2 
cells was next addressed. Analysis by real-time quantitative PCR (qPCR) 
suggested that all three PUFAs down-regulated MDR1 expression (Figure 3.2). 
The degree of down-regulation increased with incubation time, from 4 hrs to 24 
hrs. For the 24 hr incubation period, EPA treatment reduced the total mRNA level 
by ~34%, DHA treatment by 32% and AA treatment by 27%, compared to the 
solvent controls.  
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Figure 3.2. The effect of PUFAs on MDR1 gene expression. Caco-2 cells were 
incubated with 100 μM PUFAs for 4, 12, and 24 hours. mRNA levels were 
determined by qPCR (see Materials and Methods), from samples obtained from 
three independent experiments. * (P< 0.05); ** (P< 0.01); *** (P< 0.001) indicate 
significant differences from control values. 
 
To determine whether the inhibition of MDR1 expression by PUFAs occurs 
in a dose-dependent manner, effects of a second concentration (50 μM) of 
PUFAs on MDR1 gene expression were examined. Incubation of Caco-2 cells 
with 100 μM EPA produced greater inhibition of MDR1 expression than did 50 
μM EPA (Figure 3.3) at incubation times from 4 hr to 24 hr, indicating that 
inhibition of MDR1 expression by EPA is dose dependant. Similar results were 
observed for DHA and AA (data not shown). 
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Figure 3.3. The effect of EPA on MDR1 gene expression at concentrations of 50 
μM and 100 μM. MDR1 gene expression was determined by real-time 
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quantitative PCR (qPCR) using RNA samples obtained from three independent 
experiments. * (P< 0.05); ** (P< 0.01); *** (P< 0.001) indicate significant 
differences from control values.   
3.3.3. PUFAs reduce protein levels of MDR1 in Caco-2 cells 
As expected, decrease in levels of the MDR1 gene product P-gp was a 
consequence of PUFA-induced inhibition of MDR1 gene expression. Western-
blot analysis indicated that all three PUFAs reduced levels of P-gp (Figure 3.4). 
Compared to the control, the level of P-gp protein was reduced by 37% for EPA, 
by 27% for DHA, and by 48% for AA.  
      1               2              3               4            
      Ctrl      EPA   DHA    AA         
P-gp    170 kD 
β-Actin   
 
Figure 3.4. The effect of PUFAs on cellular levels of the MDR1 gene product P-
gp. Western blot analysis of P-gp (top), β-actin (bottom). Caco-2 cells were 
treated with 100 μM PUFAs for 24 hours. Lane 1, control; Lane 2, EPA; Lane 3, 
DHA; Lane 4, AA). These images are representative of three independent 
experiments.   
 
3.3.4. PUFAs inhibit the efflux function of the MDR1 gene product P-gp 
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To address whether PUFAs can affect the efflux function of MDR1, we 
examined whether PUFA-treatment affects drug accumulation in Caco-2 cells. 
Calcein-AM was used as a probe to monitor the ability of MDR1/P-gp to retain 
the fluorescent metabolite within the cells. The inhibition of activity was quantified 
by the change of intracellular fluorescence intensity of calcein. 
Exposure of the cells to PUFAs increased intracellular fluorescence by 20-
30% compared to controls (Figure 3.5). The increase was similar for all three 
PUFAs. This increase in intensity indicates that less calcein was exported from 
cells via P-gp in cells treated with PUFAs than in control cells.  
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Figure 3.5. The effect of PUFAs on calcein-AM efflux in Caco-2 cells: intracellular 
fluorescence intensity. Caco-2 cells were incubated with 100 μM of PUFA for 24 
hours followed by addition of 0.25 μM of calcein-AM. The results are averages of 
three independent experiments.  
 
3.3.5. Effect of PUFAs on cytotoxicity of the anticancer drug paclitaxel 
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To address whether the PUFA-induced reduction in the expression and 
function of MDR1 is associated with enhanced drug toxicity in cancer cells, the 
effect of the three PUFAs on the cytotoxicity of paclitaxel were studied. The 
results suggest that all three PUFAs enhance the cell toxicity of paclitaxel in a 
dose-dependant manner in Caco-2 cells (Figure 3.6). AA and EPA were in 
general more effective than DHA in increasing cell toxicity (pairwise t-test, P < 
0.01 and P < 0.05, respectively).  
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Figure 3.6. The effect of PUFAs on cytotoxicity of paclitaxel (PTX). Results are 
averages from three independent experiments.   
 
3.3.6. Effect of PUFAs on apoptosis of Caco-2 cells 
Tumor growth is often associated with defective apoptosis. Whether 
enhancement of apoptosis accompanies the effect of PUFAs on MDR1 
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expression and drug efflux was investigated. Compared to control cells, 
apoptosis was dramatically increased in cells exposed to PUFAs (Figure 3.7). 
Because induction of apoptosis is thought to be the main mechanism for the anti-
tumor effect of paclitaxel [38, 39], whether PUFAs affect the ability of paclitaxel to 
induce apoptosis was examined. Whereas exposure to paclitaxel alone induced 
only modest numbers of apoptotic cells, exposure of cells to both paclitaxel and 
PUFAs resulted in a dramatic increase in apoptosis. Further, for all three PUFAs, 
apoptosis of Caco-2 cells exposed to both paclitaxel and PUFA exceeded that of 
cells exposed to PUFA alone, suggesting that these PUFAs have the ability to 
enhance drug-induced apoptosis. 
 
Figure 3.7. The effect of PUFAs on apoptosis. Exposure to PUFAs dramatically 
increases apoptosis of Caco-2 cells and enhances paclitaxel-induced apoptosis 
in these cells. Images in Column 1 are cells incubated with solvent controls; 
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Column 2, cells treated with paclitaxel (PTX); Column 3, cells treated with PUFAs 
(from top to bottom, AA, DHA, and EPA, respectively); Column 4, cells treated 
with paclitaxel plus PUFAs (from top to bottom, AA, DHA, and EPA, respectively).  
 
3.3.7. Effect of PUFAs on the expression of the nuclear receptors CAR and PXR  
Nuclear receptor proteins that have been shown to be involved in 
transcription of drug transporters include the pregnane x receptor (PXR) and the 
constitutive androstane receptor (CAR) [21, 25]. To determine whether the 
effects of PUFAs on MDR1 are related to these known modulators of MDR1, the 
relationship between PUFA treatment and expression of CAR and PXR at the 
mRNA level in Caco-2 cells was evaluated. The results suggest that the 
expression of the CAR and PXR genes is elevated by treatment with AA, EPA, 
and DHA (Figure 3.8).  
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Figure 3.8. The effect of PUFAs on the expression of the CAR and PXR genes. 
Caco-2 cells were incubated with 100 μM of PUFA for 24 hours. Gene 
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expression was determined by real time quantitative PCR (qPCR) using RNA 
samples obtained from three independent experiments.  
 
3.4. Discussion 
 
We report here that exposure to PUFAs reduces the expression of MDR1 
in Caco-2 cells (Figure 3.3). The results also indicate that in cells with reduced 
MDR1 expression, the efflux function of MDR1/P-gp was decreased and 
paclitaxel toxicity increased (Figures 3.5 and 3.6). These observations are 
consistent with the thesis that inhibition of MDR1 gene expression accounts, at 
least in part, for the ability of PUFAs to increase the bioavailability of anticancer 
drugs, i.e. counteract MDR1-mediated drug resistance, in cancer cells.  
Since over-expression of P-gp results in lower blood drug levels and 
reduced drug diffusion into the tumor mass, one strategy suggested for 
increasing drug bioavailability involves the use of P-gp inhibitors [40]. A number 
of natural or synthetic compounds have been discovered that target P-gp, but 
these reagents produced severe side effects or low activity in vivo [41, 42]. Our 
data are consistent with previous observations that attribute the potency of ω-3 
PUFAs in drug potentiation to the ability to modulate P-gp efflux pump activity [43] 
and provide further evidence that PUFAs are valuable as potential tools to 
combat multidrug resistance. 
Treatment with PUFAs also dramatically increased apoptosis of Caco-2 
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cells (Figure 3.7), suggesting a link between decrease in P-gp expression and 
triggering of apoptotic pathways. These results are consistent with previous 
observations linking the activity of ABC-transporters, e.g. MDR1, to protection 
from apoptosis [16]. It has been reported that ω-3 PUFAs induce apoptosis by 
enhancing phospholipid oxidation and mitochondrial Ca++ accumulation [44]; 
however, the precise mechanism by which PUFAs increase apoptosis in these 
cells is unclear.  
Exposure to PUFAs also enhanced paclitaxel-induced apoptosis in Caco-2 
cells (Figure 3.7). Paclitaxel, a member of the taxane drug family, is a commonly 
used drug for the treatment of solid tumors, including ovarian, breast, head and 
neck, lung, and prostate cancer [45-48]. Paclitaxel is thought to exert a cytotoxic 
effect by binding to and inhibiting the function of mitotic microtubules [38, 39, 49, 
50], thus triggering apoptosis [51]. Cancer cells expressing MDR1/P-gp are more 
resistant to caspase-dependent apoptosis-triggering agents than normal cells [28, 
29, 52] and the known ability of MDR1/P-gp to export paclitaxel from cancer cells 
[53-55] may account for some of the paclitaxel resistance phenotypes in cancer 
patients [56]. Our results support the thesis that exposure of cells to PUFAs 
contributes to paclitaxel-induced apoptosis by increasing retention of the drug. 
Our data also suggest that ω-6 PUFAs can contribute to modulation of 
MDR. Numerous reports have indicated that ω-3 polyunsaturated fatty acids are 
beneficial in cancer treatment [3, 5, 6, 57, 58] and that differences exist between 
the effects of ω-3 and ω-6 PUFAs in cellular function and tumor progression [59]. 
 - 95 -
Notably, the ω-6 PUFA AA has been shown to stimulate rather than inhibit the 
growth of certain cancer cells, including pancreatic cancer cell growth in vitro [10]. 
Our data indicate that AA decreases expression of the MDR1 gene (Figures 3.2 
and 3.4) and that this effect is accompanied by enhancement of paclitaxel drug 
efficacy as well as increased apoptosis in Caco-2 cells (Figures 3.6 and 3.7). 
Interestingly, the extent of these effects is similar to what was observed for the ω-
3 PUFAs EPA and DHA (Figures 3.2, 3.4-3.7).  
Pregnane X receptor (PXR) and the constitutive X receptor (CAR) are 
widely recognized as determinants in the regulation of various genes involved in 
the metabolism and disposition of xeno- and endo-biotics, including multidrug 
resistance-associated transporters such as MDR1 (P-gp) [25, 60]. The induction 
of MDR1 gene expression requires PXR binding to the nuclear receptor response 
elements in the proximal promoter and/or enhancer regions [22]. CAR appears to 
be another regulator of MDR1 for expression of endogenous MDR1 is high in 
cells stably expressing CAR [24]. Current models favor the view that PXR and 
CAR affect transcription of target genes through a process involving 
heterodimerization with the retinoid x receptor (RXR) and binding to response 
elements in the promoter region of the target genes [61]. Our studies 
demonstrate that all three PUFAs up-regulate the mRNA expression of PXR and 
CAR (Figure 3.8), while reducing MDR1 gene expression (Figure 3.2). Although 
MDR1 is a potential target gene of PXR and CAR [21, 22, 24], our results 
suggest that the relationship between the mRNA level of  PXR and CAR with 
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their target gene MDR1 is not linear. PUFAs are not ligands of PXR and CAR [62, 
63], we thus hypothesize that without appropriate ligands, higher expression of 
PXR and CAR might not induce the target genes. Further examination will be 
required to test the applicability of the hypothesis in other systems. 
One difference between our study and those of others is the effect of 
PUFAs on cell viability. We observed only moderate inhibition of cell viability 
(Figure 3.1) while others have reported that PUFAs dramatically inhibit the 
growth of Caco-2 cells [35-37]. Unlike others who used a serum-poor system [35-
37], cells were cultivated with medium containing serum in this study so as to 
more closely model physiological conditions. Since serum contains polypeptide 
growth factors and other cell protective substances [64-66], differences in data 
may be due to the use of serum in our cell culture medium. The choice of PUFA 
carrier and/or the preparation of the PUFA/carrier complex may also contribute to 
differences in results among different laboratories.  
 
3.5. Conclusions 
 
Despite the extensive evidence linking dietary fat intake to certain cancers 
(e.g., breast and colon cancer), the precise molecular mechanisms by which the 
dietary ω-3 and ω-6 PUFA classes impact tumor biology have not been fully 
established. We have demonstrated that both ω-3 and ω-6 PUFAs modulate 
expression of MDR1 and increase apoptosis but the effects are CAR-, PXR-
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independent. Both ω-6 and ω-3 fatty acids can influence expression of a gene 
important in multidrug resistance is of especial current interest because the 
typical Western diet contains approximately 10 times more ω-6 than ω-3 PUFA 
[67].  
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CHAPTER IV 
DIETARY ω-3 POLYUNSATURATED FATTY ACID EPA INHIBITS PROMOTER 
DNA METHYLATION AND INCREASES GENE EXPRESSION OF BRCA1 IN 
THE HUMAN LEUKEMIC U937 CELLS  
 
ABSTRACT 
 
Despite numerous studies, the precise mechanisms by which dietary ω-3 
polyunsaturated fatty acids mediate gene expression in human cells are not clear. 
To determine whether eicosapentaenoic acid (EPA) affects BRCA1 expression 
through promoter methylation, BRCA1 DNA promoter methylation and gene 
expression in U937 cells were examined. The methylation status of the BRCA1 
promoter was evaluated by methylation-specific PCR (MSP) of bisulfite 
conversion products. The results indicate that methylation of BRCA promoter 
DNA is reduced in EPA-treated cells. The reduction of methylation in the BRCA1 
promoter was accompanied by an increase in mRNA levels obtained by real-time 
quantitative PCR (qPCR), suggesting that DNA methylation is a possible 
mechanism by which the dietary ω-3 polyunsaturated fatty acids mediate gene 
expression in human cells.  
 
4.1. Introduction 
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It is well known that ω-3 fatty acids affect various cellular processes 
including membrane composition, lipid metabolism, signal transduction and gene 
expression [1-3]. Of particular interest, ω-3 polyunsaturated fatty acids interact 
with multiple transcription factors and function as ligands for several nuclear 
receptors [4]. However, the precise mechanisms by which ω-3 polyunsaturated 
fatty acids act on gene regulation in cells are still elusive. 
DNA methylation refers to covalent addition of a methyl group at the 5' 
carbon of the cytosine ring to produce 5-methylcytosine [5]. In mammalian DNA, 
5-methylcytosine concentrates primarily at cytosine–guanine dinucleotides 
(CpGs). These methyl groups protrude into the major groove of DNA thereby 
inhibiting transcription [6]. DNA methylation plays a crucial role in development 
[7], germ-cell development [8], and tumorigenesis [9-11]. Hypermethylation of 
CpG islands within the promoters of tumor suppressor genes can cause silencing 
of the tumor suppressor genes, thereby enabling malignant growth [12].  
BRCA1 is often highly expressed in actively dividing cells and is involved 
in cell proliferation, DNA repair, genomic integrity and apoptosis [13]. Of note, 
due to promoter hypermethylation, BRCA1 expression is suppressed in 11–31% 
of breast cancers, 5–15% of ovarian cancers, 60% of pancreatic ductal 
carcinomas, and 38% of acute myeloid leukemias [14-16].  
Dietary ω-3 polyunsaturated fatty acids can be beneficial in cancer 
prevention [17-19]. Further, studies indicate that exposure to ω-3 poly-
unsaturated fatty acids can increase BRCA1 transcription and protein levels in 
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several human breast cancer cell lines [20] and in vivo [21]. Therefore, clarifying 
how ω-3 polyunsaturated fatty acids modulate BRCA1 is important.  
In this study, treating U937 cells with EPA was examined to understand 
whether methylation is decreased in the promoter region of BRCA1 and whether 
decrease in promoter methylation increases the expression of BRCA1.   
 
4.2. Materials and Methods 
 
4.2.1. Materials and reagents 
5-Aza-2′-deoxycytidine (decitabine) and the sodium salt of EPA were 
obtained from Sigma-Aldrich (St. Louis, MO) and Nu-Chek Prep Inc. (Elysian, 
MN), respectively. PCR primer oligos were obtained from Operon 
Biotechnologies (Huntsville, AL). Taq polymerase was obtained from New 
England Biolabs (Ipswich, MA). Human leukemic U937 cells (ATCC# CRL-
1593.2) were obtained from the ATCC (Manassas, VA, USA) and cultivated 
according to protocols provided by ATCC.  
 
4.2.2. Preparation of the BSA/EPA complex solution 
Serum albumin serves as carrier for free fatty acids in blood [22]. Bovine 
serum albumin, a well-studied fatty acid carrier protein in vitro [22, 23], was used 
as the EPA carrier for these studies. To prepare BSA/EPA complexes for delivery 
to cells, we used a modification of the method of Ho and Storch [24]. Briefly, 
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complexes of BSA and EPA were formed by adding the sodium salt of the EPA 
(0.01 g) to MEM medium (9mL) containing 825μM fatty acid-free BSA. The 
mixture was incubated at 37°C for 12 hr to obtain an optically clear solution, and 
aliquots of the BSA/EPA complex solution were stored under N2 gas at -20°C. 
The aliquots were filter-sterilized before addition to the experimental medium. 
The molar ratio of EPA to BSA was 4:1 [25].  
 
4.2.3. Cell viability  
Cell viability was assayed using the CellTiter-Blue® reagent (CTB, 
Promega, Madison, WI). The viability assay is based on the ability of living cells 
to convert a redox dye (resazurin) into a fluorescent end product (resorufin). 
Nonviable cells rapidly lose metabolic capacity and thus do not generate a 
fluorescent signal. U937 cells were seeded into flat-bottomed 96-well plates at a 
density of 103 cells/well in a volume of 200 μl of complete medium and were 
exposed to 10 μM Decitabine and 100 μM EPA. As controls, cells were exposed 
to complete medium with the same volume of DMSO (solvent control). After 36h 
incubation, 20μl CTB reagent was added to the wells and cells were incubated at 
370C for 4 hr before quantization of fluorescence on a Synergy HT multi-mode 
plate reader (Bio-tek Instruments, Winooski, VT) using an excitation wavelength 
of 560 nm and an emission wavelength of 590 nm. The fluorescence values were 
normalized to the controls and expressed as percent viability.  
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4.2.4. DNA isolation, bisulfite conversion and methyl-specific PCR (MSP)  
Cells were seeded at the density of 5 x105 cell/mL in T25 culture flasks 
and incubated with DMSO (solvent control), Decitabine (10 µM), or EPA (100 
µM), at 37°C in a humidified atmosphere with 5% CO2 for 24 hours. Cells were 
harvested by centrifuging at 3,000 rpm for 5 min and rinsed with PBS once 
before isolating DNA (QIAamp DNA mini kit, Qiagen, Valencia, CA) from the cell 
pellets.  
DNA was isolated from cell pellets using QIAamp DNA mini kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions. The concentrations 
and purity of the DNA samples were assessed spectrophotometrically using the 
DU 640 spectrophotometer (Beckman Coulter, Fullerton, CA). The methylation 
status of the promoter region for the two tumor suppressor genes, BRCA1 and 
p16, was determined by bisulfite conversion and methylation-specific PCR (MSP). 
Sodium bisulfite converts unmethylated cytosines to uracil and methylated 
cytosines remain unchanged. For preparation of methylated DNA, approximately 
0.6µg of DNA was treated with sodium bisulfite using EZ DNA methylation kit 
(Zymo Research, Orange, CA), followed the instruction by the manufacturer. 
An adaptation of the nested two-step approach of MSP, a modification that 
increases the sensitivity for detecting targeted sequences [26], was used here. 
The bisulfite induced sequence differences were detected using specific primer 
sets for unmethylated and methylated DNA. The primers in stage 1 were 
designed to amplify a region that is devoid of CpG nucleotides. This allowed 
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amplification independent of its methylation status. The PCR products of stage 1 
were diluted 1:300 and subjected to the second stage of MSP. In the second 
stage, two PCR reactions were performed, with one primer pair specific for 
methylated DNA (M) and the other for unmethylated DNA (U). Successful 
amplification from the M pair and the U pair indicate methylation and 
unmethylation, respectively. MSP primers for BRCA1 [26] and p16 [27], as well 
as PCR cycling information, are shown in Table 4.1. The PCR products were 
electrophoresed on 2% agarose gels, stained with ethidium bromide and 
visualized under UV illumination.   
This assay requires only 24 hours for incubating cells with reagents and 
takes an additional day to extract DNA, conduct the bisulfite reaction and PCR 
analysis. Overall, the complete assay takes less than three days.  
 
Table 4.1. MSP primer sequences and the PCR conditions 
Annealing  Annealing  Amplicon  
Gene Type Forward sequence Reverse sequence 
temp (°C) time (s) 
Cycle 
(bp) 
BRCA1 Stage1 GAGAGGTTGTTGTTTAGYGGTAGTTTT TCTAAAAAACCCCACAACCTATCC 60 40 30 143 
 M TCGTGGTAACGGAAAAGCGC AAATCTCAACGAACTCACGCCG 59 20 27 75 
 U TTGGTTTTTGTGGTAATGGAAAAGTGT CAAAAAATCTCAACAAACTCACACCA 59 20 27 86 
  mRNA GGTGGTACATGCACAGTTGC TGACTCTGGGGCTCTGTCTT 55 40 40 245 
p16 Stage1 GAGGAAGAAAGAGGAGGGGTT GCTACAAACCCTCTACCCACCTA 62 10 30 277 
 M TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 62 10 30 150 
  U TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA 62 10 30 151 
β-Actin  mRNA CATGTACGTTGCTATCCAGGC CTCCTTAATGTCACGCACGAT 55 40 40 250 
 
4.2.5. RNA extraction, reverse transcription (RT) and quantitative real-time PCR 
(qPCR) 
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U937 cells were seeded into T25 flasks at a density of 5 x 105 cells/mL 
and exposed to 10 μM Decitabine and 100 μM EPA. As controls, cells were 
exposed to complete medium with same volume DMSO. After 36h incubation, 
cells were harvested by centrifuging at 3,000 rpm for 5 min and rinsed with PBS 
once. After DNAse I treatment to remove genomic DNA, total RNA was isolated 
using the SV Total RNA isolation kit (Promega, Madison, WI) according to the 
manufacturer’s instructions. The concentrations and purity of the RNA samples 
were assessed spectro-photometrically using the DU 640 spectrophotometer 
(Beckman Coulter, Fullerton, CA). RT was performed using the reagents 
provided in the Verso cDNA kit (Abgene, Rochester, New York). The RT reaction 
mixture (20 µl) contained 1 μg total RNA, 1 µl anchored oligo-dT primer, 500 µM 
dNTP mix, 4 µl 5× cDNA synthesis buffer, 1 µl RT enhancer and 1 µl Verso 
enzyme mix. RT was performed at 42°C for 30 min and terminated by heating at 
95°C for 2 min. cDNAs were stored at -20°C.  
Real-time quantitative PCR (qPCR) for mRNA level of BRCA1 was 
conducted using an Mx3000P real-time PCR system (Stratagene, La Jolla, CA). 
The gene-specific primers (Fisher-Operon, Huntsville, AL) used for our qPCR 
reactions are listed in Table 4.1. All reactions were performed in a singleplex 
mode. The total reaction mix (20 μl) contained 10 μl 2x SYBR Green PCR master 
mix (Bio-Rad Laboratories, Hercules, CA), 200 nmol/L of each primer, and 0.8-1 
μl cDNA as template. After initial heating to 95°C for 2 min, 40 cycles were run at 
95°C for 20s, 55°C for 40s, and 70°C for 30s. Dissociation curve analyses were 
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done for all samples and only sharp melting points were observed, indicating a 
specific signal and no primer dimers or mispriming. A negative template control 
(H2O) was always included in each run to check for the presence of exogenous 
contaminant DNA. After the threshold cycle values in real-time PCR were 
obtained, the amounts of BRCA1 were determined from a standard curve 
generated by serial dilutions of cDNA. After normalization to β-actin values, the 
expression levels of BRCA1 were expressed as % of control cells. Each sample 
was analyzed in triplicate, and data were analyzed using Mx3000P software 
(Stratagene, La Jolla, CA).  
 
4.3. Results 
  
4.3.1. Effect EPA and Decitabine on the Viability of U937 Cells.  
Eicosapentaenoic acid (EPA, a 　-3 PUFA) was selected as our model for 
studying the effect of PUFAs on CpG methylation. Decitabine, a nucleoside 
inhibitor of gene activation, served as positive control. Because both of them can 
be toxic to human cell growth [28-30], cell viability studies was conducted to 
determine concentrations of EPA and Decitabine appropriate for subsequent 
experiments. U937 cells were incubated with 100μM EPA and 10μM Decitabine 
for 36 hours. Both EPA and Decitabine had a modest inhibitory effect (~ 20% of 
solvent controls) on the growth of U937 cells (Figure 4.1).  
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Figure 4.1. The effect of EPA and Decitabine on viability of U937 cells. Cells 
were incubated for 36 hours with 100 μM EPA and 10 μM Decitabine. The 
viability of treated cells is presented as the means of cell number (± SD) 
compared to control (solvent treated) cells. For each experiment, n=3. ** (P< 
0.01); *** (P< 0.001) indicate significant differences from control values. 
 
4.3.2 Effects of EPA on the promoter methylation status of the tumor suppressor 
genes BRCA1 and p16 
The methylation status of the promoter region for BRCA1 and p16 was 
determined by methylation-specific PCR (MSP) using a two-step protocol (See 
Section 4.2.4). In the solvent control cells, there was intense amplification of 
unmethylated sequences in the promoter region of BRCA1 and less but still 
ample amplification of methylated sequences (Figure 4.2). In U397 cells treated 
with Decitabine or EPA for 24h, there was a dramatic reduction in BRCA1 
methylation compared to control cells (Figure 4.2), and the degree of methylation 
appeared similar for Decitabine and EPA-treated cells.  
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 Figure 4.2. EPA and Decitabine inhibit DNA methylation of the BRCA1 gene 
promoter: Analysis of MSP products by agarose gel electrophoresis. DNA from 
U937 cells treated with 100μM EPA or 10 μM Decitabine was subjected to MSP. 
Ctrl: solvent control; U: unmethylated PCR product; M: methylated PCR product.  
 
MSP is a powerful approach for evaluating DNA methylation [31] but does 
not provide quantitative information for assessment of  methylation. To obtain 
quantification of the changes in BRCA1 methylation induced by EPA and 
Decitabine, a modified protocol based on existing quantitative MSP (qMSP) [32, 
33] was conducted. For this protocol, the products from stage 1 MSP, diluted 
1:300, served as DNA templates. Stage 2 results obtained from qPCR were 
normalized to Stage 1 products and expressed as fraction of control. qMSP 
results indicate that BRCA1 promoter methylation level decreased to 34% of 
control after treatment of U937 cells with EPA for 24h (Table 4.2). The 
methylation ratio is defined as the ratio of the fluorescence emission intensity 
values for the methylation-specific PCR products of the gene promoters to their 
stage 1-products. 
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Table 4.2. Degree of methylation of BRCA1 promoter 
Treatment ctrl Decitabine EPA 
Ratio (M /stage 1) 1 0.18*** 0.34**
 
To determine whether the effect of EPA on BRCA1 is specific, we 
performed a similar assay for the p16 gene, another well-known tumor 
suppressor [34]. Both methylated and unmethylated sequence amplification was 
detected in cells treated with Decitabine (Figure 4.3), but only methylated 
sequence was detected for p16 in EPA treated cells in a pattern similar to control 
cells.  The absence of amplification of unmethylated sequence for the p16 
promoter suggests that EPA modulation of gene methylation is not a global 
mechanism. 
 
Figure 4.3. The effect of EPA and Decitabine on DNA methylation of the p16 
gene promoter. Analysis of MSP products by agarose gel electrophoresis. DNA 
from U937 cells treated with 100μM EPA or 10 μM decitabine was subjected to 
MSP. Ctrl: solvent control; U: unmethylated PCR product; M: methylated PCR 
product.  
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4.3.3. Effects of EPA on BRCA1 gene expression in the U937 cells 
Whether EPA modulates the expression of the BRCA1 gene in U937 cells 
was addressed next. Analysis by real time PCR suggests that both EPA and 
Decitabine up-regulate BRC1 expression (Figure 4.4). For the 36 hr incubation 
period, EPA treatment increased the total mRNA level by ~50% compared to the 
solvent controls. The degree of increase is similar to that induced by Decitabine 
treatment. 
 
Figure 4.4. The effect of EPA on BRCA1 gene expression. U937 cells were 
incubated with 100 μM EPA or 10 μM Decitabine for 24 and 36 hours. mRNA 
levels were determined by qPCR (see Materials and Methods) using samples 
obtained from three independent experiments. * (P< 0.05) indicates significant 
differences from control values.  
 
4.4. Discussion 
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Certain genes, such as BRCA1, involved in tumor suppression, have been 
shown to be hypermethylated in many tumor types. The potential of dietary 
polyunsaturated fatty acid EPA to decrease methylation in the promoter regions 
of these genes was studied. Treatment of cells with EPA decreased promoter 
methylation of BRCA1 and increased expression of BRCA1 (Figures 4.2 and 4.4). 
The inhibition of promoter methylation by EPA and the effect of EPA on BRCA1 
gene expression approached levels observed for the nucleoside inhibitor of 
methylation Decitabine (Figures 4.2 and 4.4; Table 4.2). We did not detect an 
effect of EPA on the methylation status of the p16 promoter (Figure 4.3).  These 
observations indicate a specificity in the ability of EPA to modulate gene silencing. 
In order to ensure that the hypomethylation effect is not due to cell toxicity, 
cell viability assays were conducted. Both Decitabine and EPA have only a 
moderate cytotoxic effect on U937 cells within the assay time period (Figure 4.1).  
Of note, the concentration of Decitabine used in our study (10μM) is higher than 
that commonly used in other studies [35, 36]. We used the higher concentration 
of Decitabine to ensure a consistent hypomethlation effect in our screening 
model.  
The mechanism(s) by which EPA affects DNA methylation is not clear. ω-
3 polyunsaturated fatty acids are readily incorporated into cell membranes and 
lipid rafts, and their incorporation may affect membrane-associated signaling 
proteins. One hypothesis is that EPA modulates DNA methylation by interfering 
with Ras signaling for DNA methylation. Constitutive activation of Ras induces 
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expression of DNA methyl-transferase 1 (DNMT1) at the transcriptional level [37-
39] and excess of DNMT levels may target certain genes for hypermethylation.  A 
high fat fish oil diet fed to rats decreased protein levels of total and membrane 
bound Ras and increased proteins levels of cytosolic Ras in colon tumors 
compared to rats fed a high fat corn oil diet [40, 41]. This result suggests that ω-3 
PUFAs might interfere with Ras activation by decreasing its membrane 
localization. Of note, recent data implicate lipid rafts as coordinators of signals 
generating from the cell membrane and mechanisms linking DNA methylation 
and chromatin dynamics [42].  
DNA demethylating agents such as 5-azacitidine and Decitabine have 
been approved by FDA in the clinical treatment of several hematologic 
malignancies, including myelodysplastic syndromes (MDS) and acute myeloid 
leukemia (AML) [43, 44]. However, the effect of these nucleoside inhibitors on 
gene activation is non-specific and usually involved in multiple cellular pathways 
[6, 45-47]. In addition, when used in high doses, these azanucleosides can 
produce serious toxicities in patients [45, 48]. Recently, a number of dietary 
compounds have been shown to impact methylation, raising the possibility that 
an individual’s diet may also influence DNA methylation [49]. Although the 
contribution of diet to the risk of cancer is now widely acknowledged, the multiple 
possible mechanisms are only starting to be resolved [50, 51].  
 
4.5. Conclusions 
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In summary, our study clearly demonstrates that EPA inhibits promoter 
methylation and increases gene expression of BRCA1. To our knowledge, this is 
the first demonstration of such an activity for a commonly consumed dietary 
polyunsaturated fatty acid. By linking a major tumor suppressor gene associated 
with epigenetic modification to key nutritional factors involved in the incidence 
rate of the cancer, our study opens up further perspectives for the use of dietary 
interventions in cancer. 
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CHAPTER V 
SUMMARY AND RECOMMENDATIONS 
 
Accumulating evidence in both humans and animal models indicate that 
dietary intake of long-chain polyunsaturated fatty acids (PUFAs) can improve 
response to chemotherapy. The mechanisms by which PUFAs affect this 
response are not well understood. P-glycoprotein (P-gp), encoded by the 
multidrug resistance gene MDR1, is a drug efflux transporter that plays an 
important role in the bioavailability of anti-cancer drugs. We studied the effects of 
three long-chain polyunsaturated fatty acids, the ω-3 PUFAs eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) and the ω-6 PUFA arachidonic acid 
(AA) on MDR1 gene expression and functional activity in the human colon cancer 
cell line Caco-2. All three PUFAs down-regulated the expression of the MDR1 
gene. The inhibition of gene expression by these PUFAs was accompanied by 
reduction in protein levels of P-gp. EPA, DHA and AA also increased the 
intracellular accumulation (i.e. decreased the efflux) of a P-gp substrate. In 
addition, incubation of cells with PUFAs greatly enhanced the cytotoxicity of the 
anti-cancer drug paclitaxel. All three PUFAs also induced apoptosis and 
enhanced paclitaxel-induced apoptosis in Caco-2 cells. Of particular interest, our 
studies indicate that a ω-6 PUFA AA, as well as the ω-3 PUFAs EPA and DHA, 
can inhibit MDR1/P-gp expression and function. 
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Hypermethylation of promoter CpG islands is related to inhibition of gene 
expression. A thesis is that methylation (silencing) of tumor suppressor genes 
enables malignant growth. Using our protocol based on bisulfite conversion and 
methylation-specific PCR, we demonstrated that treatment of U937 cells with 
EPA decreased promoter methylation of the tumor suppressor gene BRCA1. The 
reduction of methylation in the BRCA1 promoter was accompanied by an 
increase in the mRNA levels of BRCA1, suggesting that DNA methylation is a 
possible mechanism by which the dietary ω-3 polyunsaturated fatty acids 
mediate gene expression in human cells. Treatment with EPA did not, however, 
significantly affect methylation in the p16 gene promoter, suggesting specificity 
for EPA modulation of gene methylation. 
Together these studies suggest that use of PUFAs as adjuvants presents 
a promising strategy to improve cancer therapeutics. 
 
                            Recommendations for Future Study 
 
One major findings of the study is that PUFAs inhibit MDR1/P-gp 
expression and enhance paclitaxel-induced apoptosis. However, PUFAs have no 
significant effect on modulators of MDR1 inlcuding COX-2, CAR and PXR, 
expression. This study also reveals that EPA increases the BRCA1 expression 
while at the same time decreasing promoter methylated level. Based on these 
findings, I suggest the following future studies:   
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 1. To study the effects of PUFAs on other mediators which are known to 
affect MDR1/P-gp gene expression under cetain conditions. Previous 
studies report that PUFAs can affect the activity of NF-κB. In addition, NF-
κB is one of the modulators involved in MDR1 expression. Moreover, NF-
κB is also related to apoptosis pathway. Therefore, it is important to 
examine the linkage between PUFAs, NF-κB, MDR1, and apoptosis.  
 
2. To explore the strategy of co-administration PUFAs with anti-cancer drugs 
in cancer treatment. In consideration of the interactions between PUFAs 
and anti-cancer drugs, it is important to optimize the timing for PUFA 
administrations.  
   
3. To study the effects of membrane composition changes by PUFA 
incorporation on P-gp expression. Several laboratories show that PUFAs 
can modulate cellular membrane composition and membrane 
proteins/transporters. Hence, the relationship between PUFAs and 
membrane composition is important to understand.   
 
4. To further study the relationship between promoter DNA methylation and 
MDR1 expression. Because promoter DNA methylation is one of the 
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mechanisms for gene expression, it is interesting to understand whether 
PUFAs can regulate MDR1 expression through DNA methylation.  
 
5. To study the mechanisms which are involved in changes of BRCA1 
promoter methylation pattern results from EPA treatment. For example, 
DNMTs are the major enzymes in DNA methylation. A critical question to 
address is whether EPA modulates the DNA methylation through affecting 
the DNMTs .  
 
6. To study the ability of EPA on modulating promoter DNA methylation in 
other genes or cell models. DNA methylation is highly gene- and tissue-
specific. Whether EPA affects DNA methylation in other genes and cells 
remains to be elucidated.  
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APPENDIX A 
Table A.1 Viability of Caco-2 cells treated with PUFAs 
Viability 
AA 
24h conc (μM) 25 50 100 
expt1 108.10 106.70 108.50
expt2 87.48 84.78 69.08% 
expt3 96.76 96.27 90.95
48h   
expt1 97.50 96.20 92.40
expt2 77.30 73.90 65.60% 
expt3 90.00 91.60 84.50
72h   
expt1 83.01 102.20 84.70
expt2 98.10 94.20 87.60% 
expt3 96.20 93.80 89.50
  
EPA 
24h conc (μM) 25 50 100 
expt1 94.00 90.00 91.00
expt2 97.00 75.00 87.00
expt3 96.00 76.00 67.00
expt4 95.00 92.00 85.00
% 
expt5 98.67 96.01 91.26
48h   
expt1 99.00 81.00 78.00
expt2 91.00 64.00 63.00% 
expt3 97.00 92.00 88.00
72h   
expt1 99.00 83.00 67.00
expt2 97.31 94.22 88.78% 
expt3 75.60 89.70 86.10
  
DHA 
24h conc (μM) 25 50 100 
expt1 92.07 99.41 121.44
expt2 89.10 81.90 74.32% 
expt3 95.64 100.66 101.13
48h   
expt1 105.36 110.61 116.2
expt2 85.95 74.66 72.94% 
expt3 86.00 84.67 87.41
72h   
expt1 92.32 91.6 92.44
expt2 85.52 80.23 68.66% 
expt3 97.22 94.82 89.69
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Table A.2 Gene expression of MDR1 in Caco-2 cells treated with PUFAs 
 
MDR1 
100μM AA 4h 12h 24h 
expt1 1.04  0.71  0.79 
expt2 0.83  0.7  0.74 fold change 
expt3 0.76  0.77  0.67 
  
100μM EPA 4h 12h 24h 
expt1 0.89  0.72  0.62 
expt2 0.83  0.68  0.67 
expt3 0.8  0.77  0.7 
fold change 
expt4 0.83  0.7    
  
100μM DHA 4h 12h 24h 
expt1 0.95  0.85  0.56 
expt2 0.95  0.92  0.75 fold change 
expt3 0.93  0.97  0.71 
            
50μM EPA 4h 12h 24h 
expt1 0.97  0.9  0.91 
expt2 0.97  1.05  0.8 fold change 
expt3 1.07  0.9  0.83 
 
 
 
Table A.3 Intensity (%) of Calcein-AM efflux in Caco-2 cells treated with PUFAs 
 
 
Calcein-AM efflux 
24h 
  expt1 expt2 expt3 
AA 149.06 129.37 97.06
EPA 122.25 118.81 137.68% 
DHA 133.41 134.19 126.48
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Table A.4 Viability of Caco-2 cells treated with paclitaxel (PTX) with/without 
PUFAs for 72h 
 
72h, % 
PTX alone 
0 100.00% 100.00% 100.00%
1 103.19% 83.93% 101.68%
2.5 104.15% 88.87% 96.99%
5 98.26% 82.97% 78.41%
10 91.56% 87.98% 79.37%
25 86.20% 77.80% 63.84%
50 83.27% 78.18% 57.51%
100 77.33% 81.60% 40.48%
  
PTX+ 100μM AA 
0 83.24%   83.60%
1 61.18%   63.69%
2.5 57.71% 56.23% 65.27%
5 50.63% 48.08% 59.15%
10 44.28% 43.09% 53.57%
25 40.83% 43.12% 47.34%
50 58.35% 35.11% 41.13%
100 60.49% 30.54% 45.27%
  
PTX+ 100μM EPA 
0 90.53%   107.77%
1 70.79%   84.71%
2.5 66.33% 45.42% 85.01%
5 64.59% 36.66% 65.23%
10 62.86% 29.56% 61.03%
25 52.57% 24.44% 55.82%
50 48.02% 19.91% 46.51%
100 49.26% 17.78% 41.00%
  
PTX+ 100μM DHA 
0 121.16% 120.90% 118.71%
1 96.07% 88.31% 93.84%
2.5 83.81% 86.00% 89.63%
5 77.26% 81.70% 76.21%
10 64.09% 62.45% 68.12%
25 57.20% 54.76% 60.87%
50 44.18% 47.27% 52.23%
100 38.75% 40.31% 42.52%
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Table A.5 Gene expression of CAR and PXR in Caco-2 treated with PUFAs for 
24h 
 
  CAR PXR 
100μM AA EPA DHA AA EPA DHA 
1.528 1.296 1.077 2.022 1.190 1.541 
1.209 1.233 1.459 1.804 1.582 1.041 
1.400 1.402 1.156 1.560 2.503 1.241 
fold 
change 
        1.848   
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APPENDIX B 
 
Table B.1 Viability of U937 cells treated with Decitabine and EPA for 36h 
 
Viability of U937 (%) 
ctrl 100 100 100 
Decitabine, 10μM 90.5 81.9 80.6 
EPA, 100μM 73 75.8 75.8 
 
 
Table B.2 qMSP of BRCA1 promoter in U937 cells treated with Decitabine and 
EPA for 24h 
 
qMSP, 24h 
  Decitabine EPA 
expt1 0.22 0.56 
expt2 0.31 0.12 
expt3 0 0.35 
 
Table B.3 Gene expression of BRCA1 in U937 cells treated with Decitabine and 
EPA for 24h and 36h 
 
BRCA1, 24h 
  Decitabine EPA 
expt1 0.83 1.28 
expt2 0.85 1.06 
expt3 1.7 1.38 
BRCA1, 36h 
  Decitabine EPA 
expt1 1.98 1.59 
expt2 1.59 1.24 
expt3 1.47 1.69 
expt4 1.21   
 
 
 
 
 
 
 
 
 
 
